Carcinoma, a fibrolamellar variant - Immunohistochemical analysis of 4 cases

Hepato-Gastroenterology

Volumn 52, Issue 62, 2005, Pages 519-523

  Górnicka, Barbara ^a   Ziarkiewicz Wróblewska, Bogna ^a   Wróblewski, Tadeusz ^a   Wilczynski, Grzegorz Marek ^a   Koperski, Lukasz ^a   Krawczyk, Marek ^a   Wasiutynski, Aleksander ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Hepatocellular carcinoma fibrolamellar variant; Immunohistochemistry

Indexed keywords

CALCITONIN; CD34 ANTIGEN; CHROMOGRANIN A; CYCLIN D1; CYCLINE; CYTOKERATIN; CYTOKERATIN 19; CYTOKERATIN 7; EPSTEIN BARR VIRUS ANTIGEN; INSULIN; KI 67 ANTIGEN; PARATHYROID HORMONE; PROTEIN BCL 2; SYNAPTOPHYSIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SURGERY; CASE REPORT; CELL PROLIFERATION; CORRELATION ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INFECTION;

ADULT; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KERATINS; LIVER NEOPLASMS; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; VIRAL MATRIX PROTEINS;

EID: 16344368273     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Klatskin G, Conn HO: Histopathology of the liver. New York: Oxford University Press, 1993.
2. MacSween RNM, Burt AD, Portmann BC, et al: Pathology of the liver. London: Churchill Livingstone, 2002.
3. Craig JR, Peters RL, Edmondson HA, Omata M: Fibrolamellar carcinoma of the liver: a tumor of adolescents and adults with distinctive clinicopathologic features. Cancer 1980; 46:372-379.
4. Wang J, Dhillon AP, Sankey EA, et al: "Neuroendocrine" differentiation in primary neoplasm of the liver. J Pathol 1991; 163:61-67.
5. Ishak KG, Goodman ZD, Stocker JT: Atlas of Tumor Pathology in Tumors of the Liver and Intrahepatic Bile Ducts. Washington: Armed Forces Institute of Pathology, 2001.
6. Van Eyken P, Sciot R, Brock P, et al: Abundant expression of cytokeratin 7 in fibrolamellar carcinoma. Histopathology 1990; 17:101-107.
7. Berman MA, Burnham JA, Sheahan DG: Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and review of the literature. Hum Pathol 1988; 19:784-794.
8. Saab S, Yao F: Fibrolamellar hepatocellular carcinoma. Case report and review of literature. Dig Dis Sci 1996; 41:1981-1985.
9. Cotran RS, Kumar V, Robbins SL: Pathologic basis of disease. Philadelphia: Saunders Company, 1994.
10. Kawiak J, Zabel M: Seminaria z cytofizjologii. Wroclaw: Urban&Partner, 2002.
11. Sato Y, Itoh F, Hareyama M, et al: Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol 1999; 34:486-493.
12. Nishida N, Fukuda Y, Komeda T, et al: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54:3107-3110.
13. Zhang YJ, Chen SY, Chen CJ, Santella RM: Polymorphism in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002; 33:125-129. (Abstract)
14. Choi YL, Park SH, Jang JJ, Park CK: Expression of G1 modulators in hepatitis B virus related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma. J Korean Med Sci 2001; 16:424-432. (Abstract)
15. Azechi H, Nishida N, Fukuda Y, at al: Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 2001; 60:346-354.
16. Zhang YJ, Jiang W, Chen CJ, et al: Amplification and overexpression of cyclin D1 in human hepatocellular hepatocarcinoma. Biochem Biophys Res Commun 1993; 196:1010-1016. (Abstract)
17. Deane NG, Parker MA, Aramandla R, et al: Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mouse. Cancer Res 2001; 61:5389-5395.
18. Vo QN, Geradts J, Gulley ML, et al: Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J Clin Pathol 2002; 55:669-675.
19. Van Eyken P, Sciot R, Paterson A, et al: Cytokeratin expression and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988; 19:562-568.
20. Vora JM, Amarapurkar AD, Rege JD, Mathur SK: Neuroendocrine differentiation in hepatocellular carcinoma. Indian J Gastroenterol 2000; 19:37-38. (Abstract)
21. LIoreta J, Vadell C, Fabregat X, Serrano S: Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid. Ultrastruct Pathol 1994; 18:287-292.
22. Zhao M, Laissue JA, Zimmermann A: "Neuroendocrine" differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol 1993; 8:617-626.
23. Dadke D, Jaganath P, Krishnamurthy S, Chiplunkar S: The detection of HBV antigens and HBx-transcripts in an Indian fibrolamellar carcinoma patient: a case study. Liver 2002; 22:87-91.
24. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, et al: Fibrolamellar hepatocellular carcinoma in Mexican patients. Pathol Oncol Res 2002; 8:133-137.
25. Yoshida K, Amemiya M, Kobayashi S, et al: Fibrolamellar carcinoma of the liver in the Orient. J Surg Oncol 1988; 39:187-189.
26. Davidson FD, Fagan EA, Portmann B, Williams R: HBV-DNA sequences in tumor and nontumor tissue in a patient with fibrolamellar variant of hepatocellular carcinoma. Hepatology 1990; 12:676-679.